当前位置: 首页 >> 检索结果
321. Comparing the Efficacy of Sirolimus and Paclitaxel-Eluting Balloon Catheters in the Treatment of Coronary In-Stent Restenosis: A Prospective Randomized Study (TIS 2 Study).
作者: Leos Pleva.;Pavel Kukla.;Tomas Kovarnik.;Jana Zapletalova.
来源: Circ Cardiovasc Interv. 2025年18卷5期e014677页
Current therapy for in-stent restenosis (ISR) is based on drug-eluting stents (DES) or drug-eluting balloon catheters. This prospective randomized study compared the efficacy of a novel sirolimus-eluting balloon (SEB) catheter to that of a paclitaxel-eluting balloon (PEB) catheter for the treatment of bare-metal stent (BMS-ISR) or DES-ISR.
322. Two-Year Clinical Outcomes in Female and Male Patients After Sirolimus-Coated Balloon Angioplasty for Coronary Artery Disease.
作者: Pier Pasquale Leone.;Luca Testa.;Antonio Greco.;Lee C Yan.;Diego Milazzo.;Susanna Benincasa.;Dario Gattuso.;Bernardo Cortese.; .
来源: Circ Cardiovasc Interv. 2025年18卷6期e014814页 325. Sex-Specific Impact of Angiotensin Receptor Blockers on the Progression of Aortic Stenosis in Patients With Hypertension: Results From the HYTAS Study.
作者: Karolanne Demers.;Kathia Abdoun.;Philippe Pibarot.;Lionel Tastet.;Mulham Ali.;Erwan Salaun.;Paul Poirier.;Andréanne Powers.;Jordi Sanchez Dahl.;Jonathan Beaudoin.;Marie-Annick Clavel.
来源: Circ Cardiovasc Imaging. 2025年18卷5期e017913页 326. Atypical Presentation of an Increasingly Recognized Disease: Transthyretin Amyloidosis Presenting With 18F-Fluorodeoxyglucose Uptake on Cardiac Positron Emission Tomography and Focal Late Gadolinium Enhancement on Cardiac Magnetic Resonance.
作者: Kyla Brezitski.;Karen Flores Rosario.;Han W Kim.;Johana R Fajardo.;Michel G Khouri.;Salvador Borges-Neto.;Ravi Karra.
来源: Circ Heart Fail. 2025年18卷6期e012002页 328. Lymphatic Endothelial Branched-Chain Amino Acid Catabolic Defects Undermine Cardiac Lymphatic Integrity and Drive HFpEF.
作者: Xiong Guo.;Chong Huang.;Ling Zhang.;Guangyu Hu.;Yunhui Du.;Xiyao Chen.;Fangfang Sun.;Tongzheng Li.;Zhe Cui.;Congye Li.;Yongzhen Guo.;Wenjun Yan.;Yunlong Xia.;Shan Wang.;Hui Liu.;Zhiyuan Liu.;Zhen Lin.;Xinyi Wang.;Zhengyang Wang.;Fuyang Zhang.;Ling Tao.
来源: Circulation. 2025年151卷23期1651-1666页
Heart failure with preserved ejection fraction (HFpEF) has become the most prevalent type of heart failure, but effective treatments are lacking. Cardiac lymphatics play a crucial role in maintaining heart health by draining fluids and immune cells. However, their involvement in HFpEF remains largely unexplored.
329. A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure.
作者: Signe Glargaard.;Jakob Hartvig Thomsen.;Christian Tuxen.;Matias Greve Lindholm.;Christian Axel Bang.;Morten Schou.;Kasper Iversen.;Rasmus Vedby Rasmussen.;Brian Bridal Løgstrup.;Søren Vraa.;Nis Stride.;Ekim Seven.;Anders Barasa.;Marlene Tofterup.;Dan Eik Høfsten.;Kasper Rossing.;Lars Køber.;Finn Gustafsson.;Jens Jakob Thune.
来源: Circulation. 2025年151卷16期1150-1161页
TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion-Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion.
330. Olmesartan Restores LMNA Function in Haploinsufficient Cardiomyocytes.
作者: Eric J Kort.;Nazish Sayed.;Chun Liu.;Gema Mondéjar-Parreño.;Jens Forsberg.;Emily Eugster.;Sean M Wu.;Joseph C Wu.;Stefan Jovinge.
来源: Circulation. 2025年151卷20期1436-1448页
Gene mutations are responsible for a sizeable proportion of cases of heart failure. However, the number of patients with any specific mutation is small. Repositioning of existing US Food and Drug Administration-approved compounds to target specific mutations is a promising approach to efficient identification of new therapies for these patients.
331. Long-Term Effects of Mavacamten on Patients Based on Hypertrophic Cardiomyopathy Pathogenic Genetic Variant Status: Insights From VALOR-HCM Trial.
作者: Milind Y Desai.;Anjali Owens.;Sara Saberi.;Andrew Wang.;Kathy Wolski.;Paul C Cremer.;Neal K Lakdawala.;Albree Tower-Rader.;Mark Zenker.;Mark Sherrid.;Jeffrey B Geske.;David Fermin.;Srihari S Naidu.;Kathy Lampl.;Steven E Nissen.; .
来源: Circ Genom Precis Med. 2025年18卷3期e005100页 332. Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial.
作者: Brian R Lindman.;Philippe Pibarot.;Allan Schwartz.;J Bradley Oldemeyer.;Yan Ru Su.;Kashish Goel.;David J Cohen.;William F Fearon.;Vasilis Babaliaros.;David Daniels.;Adnan Chhatriwalla.;Hussam S Suradi.;Pinak Shah.;Molly Szerlip.;Michael J Mack.;Thom Dahle.;William W O'Neill.;Charles J Davidson.;Raj Makkar.;Tej Sheth.;Jeremiah Depta.;James T DeVries.;Jeffrey Southard.;Andrei Pop.;Paul Sorajja.;Rebecca T Hahn.;Yanglu Zhao.;Martin B Leon.;Philippe Généreux.; .
来源: Circulation. 2025年151卷22期1550-1564页
The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) intervention was superior to clinical surveillance with delayed TAVR in patients with asymptomatic severe aortic stenosis. Cardiac biomarkers are associated with maladaptive remodeling, symptom onset, and worse outcomes after TAVR. Whether elevated biomarkers identify asymptomatic patients more likely to benefit from early intervention is unknown.
333. Correction to: 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines.
作者: Sunil V Rao.;Michelle L O'Donoghue.;Marc Ruel.;Tanveer Rab.;Jaqueline E Tamis-Holland.;John H Alexander.;Usman Baber.;Heather Baker.;Mauricio G Cohen.;Mercedes Cruz-Ruiz.;Leslie L Davis.;James A de Lemos.;Tracy A DeWald.;Islam Y Elgendy.;Dmitriy N Feldman.;Abhinav Goyal.;Ijeoma Isiadinso.;Venu Menon.;David A Morrow.;Debabrata Mukherjee.;Elke Platz.;Susan B Promes.;Sigrid Sandner.;Yader Sandoval.;Rachel Schunder.;Binita Shah.;Jason P Stopyra.;Amy W Talbot.;Pam R Taub.;Marlene S Williams.
来源: Circulation. 2025年151卷13期e865页 335. Correction to: Prenatal Lipopolysaccharides Exposure Induces Transgenerational Inheritance of Hypertension.
作者: Nian Cao.;Cong Lan.;Caiyu Chen.;Zaicheng Xu.;Hao Luo.;Shuo Zheng.;Xue Gong.;Hongmei Ren.;Zhuxin Li.;Shuang Qu.;Cheng Yu.;Jining Yang.;Pedro A Jose.;Yundai Chen.;Gengze Wu.;Cuimei Hu.;Junyi Yu.;Chunyu Zeng.
来源: Circulation. 2025年151卷13期e866页 336. Correction to: Clinical Considerations for Competitive Sports Participation for Athletes With Cardiovascular Abnormalities: A Scientific Statement From the American Heart Association and American College of Cardiology.
作者: Jonathan H Kim.;Aaron L Baggish.;Benjamin D Levine.;Michael J Ackerman.;Sharlene M Day.;Elizabeth H Dineen.;J Sawalla Guseh.;Andre La Gerche.;Rachel Lampert.;Matthew W Martinez.;Michael Papadakis.;Dermot M Phelan.;Keri M Shafer.; .
来源: Circulation. 2025年151卷13期e864页 337. Correction to: Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association.
作者: Pei-Ni Jone.;Adriana Tremoulet.;Nadine Choueiter.;Samuel R Dominguez.;Ashraf S Harahsheh.;Yoshihide Mitani.;Meghan Zimmerman.;Ming-Tai Lin.;Kevin G Friedman.; .
来源: Circulation. 2025年151卷13期e863页 338. Response by Yu and Cheng to Letter Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial".340. Letter by Kakizaki and Räber Regarding Article, "Effect of Colchicine on Coronary Plaque Stability in Acute Coronary Syndrome as Assessed by Optical Coherence Tomography: The COLOCT Randomized Clinical Trial". |